You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (GenomeWeb) – Kirkland, Washington-based Prevencio is working on finishing development of its multi-protein test for coronary artery disease and is aiming to submit the test to the US Food and Drug Administration in 2018.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.